Progyny, Inc. (PGNY) stock
PGNYNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 21/305% below fair value
$36.18−0.40 (-1.09%)
Close on Nov 13, 2026Market cap $2.78BP/E 33.2Yield –
Progyny r&d expenses
Research and development expenses are spending on new products and technology.
Progyny's R&D Expenses for the twelve months ending Sep 30, 2026 was $12.30M. For fiscal 2025 it was $9.50M.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.10M | +19.2% |
| Q2 FY2026 | Jun 30, 2026 | $3.30M | +43.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.80M | +86.7% |
| Q4 FY2025 | Dec 31, 2025 | $3.10M | – |
| Q3 FY2025 | Sep 30, 2025 | $2.60M | – |
| Q2 FY2025 | Jun 30, 2025 | $2.30M | – |
| Q1 FY2025 | Mar 31, 2025 | $1.50M | – |
See a number that looks wrong?